Juvenile idiopathic arthritis (JIA) is the most common autoimmune inflammatory disease in children; joint inflammation is the hallmark of the disease. Thirty-five children with JIA were studied, of whom 26 had active disease and 14 were receiving anti-TNF therapy (5 with Infliximab, 9 with Etanercept). Sixteen healthy controls also were studied. Saliva samples were obtained for analysis of anti-oxidant status, metalloproteinases (MMPs) and sialochemistry. The total antioxidant status was significantly higher in the saliva of all JIA patients, whether treated (P = 0.014) or not treated (P = 0.038) with anti-TNF agents. The increase in antioxidant status (TAS) in the saliva of the active patients was nearly two times higher than that of non-active patients (P = 0.01). MMP levels were significantly lower in JIA patients than in controls. MMP-9, MMP-3 and MMP-2 were lower in JIA patients without anti-TNF treatment by 36.7% (P = 0.01), 30.0% (P = 0.0001) and 10.7% (P = 0.0001), respectively. A greater reduction in MMP levels was observed in the group of patients treated with anti-TNF drugs: MMP-9, MMP-3 and MMP-2 were lower than in controls by 51.1% (P = 0.0001), 61.5% (P = 0.0001) and 55.4% (P = 0.0001), respectively. Children with JIA exhibited a significantly higher salivary antioxidant activity and significantly lower MMP levels. Anti-TNF treatment was associated with a further decrease in MMP levels in the saliva of JIA patients while an active state of JIA was associated with a further increase in the salivary antioxidant activity. Anti-TNF treatment may modulate the degradation process during the course of arthritis by inhibition of the activity of MMP .
INTRODUCTION
Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children, with at least three primary modes of onset: systemic, polyarticular and oligoarticular types (1) . The severity of the disease varies between its active and nonactive states and follow up requires multiple blood tests, which can be a major drawback in children. The pathogenesis of JIA is characterized by prolonged chronic inflammation of the synovial membranes, accompanied by recruitment of mononuclear cells and phagocytes into the synovial fluid (2) . The accompanying T-cell abnormalities and pathological characteristics of this chronic synovitis suggest an immune cell-mediated pathogenesis (3) . Indeed, proinflammatory cytokines such as TNF-α have been found to play a pivotal role in the pathogenesis of JIA, and anti-TNF drugs are used routinely in the clinical setup (4) (5) (6) . Two of these anti-TNF drugs are Infliximab (Schering-Plough Ltd, Shire Park, Welwyn Garden City, Hertfordshire, UK) and Etanercept (Wyeth Pharmaceuticals, Maidenhead, Berkshire, UK), which differ in both mechanism of action as well as level of their related side effects (6) . Both drugs have their drawbacks: aside from their high cost, they become less effective as therapy continues and their dosage often needs to be altered or even replaced with the other drug. This situation requires intensive follow-up and multiple blood tests carried out by professional medical personnel. Therefore, salivary testing would be a major advantage due to its noninvasive nature, which would be much less traumatic for the child and could even be done at home (7, 8) .
Oxidative stress is increasingly recognized as one of the major factors contributing to the chronic inflammatory process within the inflamed joint. We have previously reported increased activity of antioxidant enzymes in the serum and saliva of JIA patients and other salivary alterations, indicating a specific disruption of the salivary glands as part of the JIA pathogenesis (9) . Also, Walton et al. (10) previously reported salivary gland involvement in JIA, expressed by a decrease in both salivary flow rates. In yet another study, our group found that the antioxi-dant profile of saliva secreted by rheumatoid arthritis (RA) patients showed remarkably increased levels of antioxidant enzymes both in saliva and in serum, especially in severely affected patients, and also a decrease in salivary rate (11) . Furthermore, involvement of the salivary glands in adults with RA has been recognized for quite some time. Minor salivary glands of RA patients have been shown to be infiltrated markedly with lymphocytes, with B cells predominating over T cells (12) . Other studies showed that the typical minor salivary gland alterations in RA include fibrosis, acinar atrophy and lympho-plasma cell sialadenitis (13) . In other studies, it has been reported that matrix metalloproteinases (MMPs) 2, 3 and 9 were found to be increased in the serum and in the synovial fluid of JIA patients (14) (15) (16) (17) . The MMPs are a family of zincdependent endopeptidases capable of degrading all components of the extracellular matrix, and MMPs contribute significantly to tissue destruction. The pathognomonic destruction of cartilage and bone in JIA is mediated largely by proteolytic enzymes, among which the MMPs play a critical role (15, 18, 19) .
MMPs have not been studied in the saliva of JIA patients nor as part of a salivary antioxidant profile and/or composition in JIA patients. Neither have MMPs been studied with respect to the activity status of JIA or the effects of the anti-TNF therapy. The purpose of the current study was to conduct a comprehensive salivary antioxidant and compositional analysis and examination of MMPs in JIA patients, and to correlate these to both the activity status of the disease and the effects of anti-TNF therapy.
MATERIALS AND METHODS

Patients and Methods
This study was approved by the Human Studies Ethics Committee of Rambam Medical Center, Haifa, and each participant's parent signed an informed consent form. Thirty-five patients with JIA according to the International League of Associations for Rheumatology (ILAR) criteria (20) participated in the study, 28 females and 7 males, with a mean age of 12.1 ± 3.9 years old. None of the patients suffered from any kind of local oral inflammatory disease or from any other systemic disease other than JIA. Of the 35 patients, 7 had systemic, 14 had polyarticular and 14 had pauciarticular course of disease, while 26/35 had active disease and 9/35 had non-active JIA, as defined by established criteria, at the time of the study (21) . All the patients were followed up at the Pediatric Rheumatology Clinic, Meyer Children's Hospital, by the same pediatric rheumatology expert (RB). Of the 35 patients, 17 had long-standing disease (> 5-year duration) while 2 were treatment free, 17 were on methotrexate (MTX; Hospira UK Ltd, Queensway, Royal Leamington Spa, Warwickshire, UK) and 14 received anti-TNF therapy (5 with Infliximab and 9 with Etanercept). Sixteen age-matched children (mean age 12.19 ± 3.09 years old) constituted the control group. Saliva samples were obtained from each participant and stored for analysis, as previously described by Brik et al. (9) .
Immunoreactivity Assay (ELISA) for MMP Levels
Saliva samples were centrifuged (800g, 10 min, 4°C), and the pellets were suspended in 150 μL of lysis buffer (45 mM HEPES, 0.4 M KCl, 1 mM EDTA, 10% glycerol, pH 7.8). Following 30 min incubation at room temperature, the samples were centrifuged (11,000g, 10 min, 4°C). Protein concentrations in the supernatants were determined. A volume containing 50 ng of protein was transferred to a 1.5-mL vial and all samples were brought to the same volume of 500 μL with the addition of PBS. The solutions were mixed well and 100 μL of each sample was added to enzyme-linked immunosorbent assay (ELISA)-plate wells (nunc-immunoplate; Thermo Fisher Scientific). The plate was covered and stored overnight at 4°C. The next day, each well was washed three times with 100 μL PBSTween solution (PBS-T, PBS containing 0.05% Tween 20) and a volume of 100 μL of 1% BSA PBS-T blocking solution (PBS containing 0.05% Tween 20 and 1% BSA) was added to each well. After 1 h incubation at room temperature, 100 μL of primary antibody was added to each well. For MMP9 we used a monoclonal rabbit anti-human antibody (1:1000; SigmaAldrich, Saint Louis, MO, USA). For MMP3 we used a monoclonal rabbit antihuman antibody (1:500; Sigma-Aldrich, Saint Louis, MO, USA). For MMP2 we used a monoclonal rabbit anti-human antibody (1:1000; Sigma-Aldrich, Saint Louis, MO, USA). Following 2 h incubation at room temperature, the plate was washed as described above and a volume of 100 μL of peroxidase-conjugated goat anti-rabbit secondary antibody (1:5000; Jackson Immunoresearch, West Grove, PA, USA) was added to each well. Following 2 h incubation at room temperature, the plate was washed as described above. To achieve color development, we added 100 μL of 3,3′,5,5′-tetramethylbenzidine solution (TMB) (Southern Biotech) to each well. After 1-2 min, we added 100 μL of stopping reagent to each well (10% sulphuric acid). Absorbencies of the samples were measured at 450 nm directly after the addition of the stopping reagent, using a Zenith 200 ELISA reader (Anthos, Eugendorf, Austria).
General Sialochemistry and Oxidative Analysis
The salivary analysis was performed as previously described (9, 22) and included calcium (Ca), phosphate (P) and total protein (TP) as well as a comprehensive salivary oxidative analysis. The analysis included (a) two general measurements of salivary antioxidant potential: total antioxidant status (TAS) and ImAnOx; (b) one antioxidative molecule: uric acid (UA) and (c) two antioxidant enzymes: superoxide dismutase (SOD) and salivary peroxidase (SPO). Analysis also included one oxidative parameter-carbonyls-which represents the oxidative damage to proteins.
TAS
The assay used was based on a commercial kit supplied by Randox (USA) in which metmyoglobin in the presence of iron is turned into ferrylmyoglobin. Incubation of the latter with the Randox reagent ABTS results in the formation of a blue-green colored radical which can be detected at 600 nm (23) .
Imanox
An ELISA colorimetric test kit (Immundiagnostik AG, Bensheim, Germany) was used to measure total salivary antioxidative capacity quantitatively, as described previously (24) . Briefly, saliva samples were added to a defined amount of exogenous hydrogen peroxide (H 2 O 2 ), partial elimination of the latter. The residual H 2 O 2 was determined by an enzymatic reaction involving the conversion of tetramethylbenzidine (TMB) to a colorimetric product. Following addition of a stop solution to the samples, absorbance was measured at 450nm, using a Zenith 200 ELISA reader (Anthos, Eugendorf, Austria). To quantify the absorbance values, we used a calibrator provided by the manufacturer.
UA Concentration
Uric acid concentration was measured with a kit supplied by Sentinel CH (Milano, Italy) as previously described (23) . In the assay, uric acid is transformed by uricase into allantoin and hydrogen peroxide, which, under the catalytic influence of peroxidase, oxidizes the chromogen (4-aminophenazone/ N-ethylmethylanilin propan-sulphonate sodic). This reaction forms a red compound whose intensity of color is proportional to the amount of uric acid present in the sample and is read at a wavelength of 546 nm.
SPO
Peroxidase activity was measured in both the patients' serum and saliva according to the NBS assay as described previously (23) . Briefly, the colorimetric change induced by the reaction between the enzyme and the substrate, Dithiobis 2-Nitrobensoic Acid (DTNB) in the presence of mercapto-ethanol, was read at a wavelength of 412 nm for 20 s.
SOD
Total activity of SOD isoenzymes (Cu/Zn-SOD and Mn-SOD) was measured using the xanthine oxidase/2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) method. This method is a spectrophotometric assay for SOD based on tetrazo lium salt 3′- [ . One unit of the enzyme is defined as the amount of enzyme needed for 50% inhibition of absorption in the absence of the enzyme (23) .
Detection of Protein Oxidation (Protein Carbonyl Assay)
An ELISA colorimetric test kit (Cayman Chemical, New Zealand) was used to quantitatively measure the products of protein oxidation (carbonyls) in saliva samples. Saliva samples were centrifuged (800g, 10 min, 4°C), and the pellets were suspended in 150 μL of lysis buffer (45 mM HEPES, 0.4 M KCl, 1 mM EDTA, 10% glycerol, pH 7.8). Following 30 min incubation at room temperature, the samples were centrifuged (11,000g, 10 min, 4°C) and the supernatants were stored at -20°C. On the day of the carbonyl analysis, the supernatants were thawed and protein concentrations were determined. A total of 20 μg was transferred to a 1.5-mL vial and all samples were brought to the same volume of 100 μL with the addition of water of high pressure liquid chromatography grade (HPLC). We added 0.8 volumes of ice cold 28% trichloroacetic acid (TCA), mixed well, and after 10 min of incubation on ice, the tubes were centrifuged (10,000g, 3 min, 4°C). Supernatants were aspirated carefully without disturbing the pellet; 5 μL of EIA buffer (1 M phosphate solution containing 1% BSA, 4 M NaCl, 10 mM EDTA and 0.1% sodium azide) and 15 μL diluted 2,4-dinitrophenol (DNP) solution were added to samples according to the manufacturer's instructions. Following 45 min incubation at room temperature, 5 μL of each sample were taken to a parallel set of 1.5-mL vials containing 1 mL EIA buffer. The solutions were mixed thoroughly and 200 μL of each sample was added to ELISAplate wells. The plate was covered and stored overnight at 4°C. The next d, the plate was washed three times with EIA buffer (250 μL per well) and 250 μL of diluted blocking solution (provided by the manufacturer) was added to each well. After 30 min incubation at room temperature, the wells were washed as described above and 200 μL of diluted anti-DNP-biotin-antibody was added to each well. The plate was incubated for 1 h at 37°C. Following incubation, the plate was washed and 200 μL of diluted streptavidin-HRP were added to each well. After 1 h incubation at room temperature the plate was washed as described above. To achieve color development, we added 200 μL of chromatin reagent (provided by the manufacturer) to each well. After 5 min, we added 100 μL of stopping reagent to each well. Absorbencies of the samples were measured at 450 nm directly after the addition of the stopping reagent, using a Zenith 200 ELISA reader (Anthos). To quantify the absorbance values, we performed the same procedure for standard and control samples provided by the manufacturer, and created a standard curve.
Statistical Analysis
Data concerning the levels of various parameters evaluated in saliva were observed and calculated. Because of the large inborn variability of parameters in saliva, median values were calculated. The results of saliva parameters between subgroups of patients (two or more) were compared by the Kruskal-Wallis test (a multiple-comparison nonparametric test). The correlation coefficients between the pairs of salivary parameters levels were analyzed using the Spearman correlation analysis. Sensitivity and specificity values were calculated as the fraction of obser-vations, which were correctly classified. A P value smaller than 0.05 was regarded as statistically significant.
RESULTS
MMP Levels
A significant decrease of MMPs evaluated was found in JIA patients compared with control healthy children. The median values of MMP-9, MMP-3 and MMP-2 in the controls were 0.994, 0.668 and 0.524, respectively. In the JIA children these values were lower by 52.2% (P = 0.0001), 36.2% (P = 0.0001) and 47.2% (P = 0.0001), respectively. The reduction in the MMP levels was even greater in JIA children being treated with anti-TNF therapy as compared with those untreated (without anti-TNF). The median MMP-9, MMP-3 and MMP-2 levels were lower in JIA patients without anti-TNF treatment by 36.7% (P = 0.01), 30.0% (P = 0.0001) and 10.7% (P = 0.0001), respectively. A greater reduction in MMP levels was observed in the group of patients treated with anti-TNF drugs: median MMP-9, MMP-3 and MMP-2 levels were lower than in controls by 51.1% (P = 0.0001), 61.5% (P = 0.0001) and 55.4% (P = 0.0001), respectively.
The salivary median concentrations of MMP-2, MMP-3 and MMP-9 in the anti-TNF treated children were 0.234, 0.411 and 0.424, respectively, lower by 50% (P = 0.0006), 12.2% (P = 0.048) and 29.1% (P = 0.036) than in the untreated children (which were lower than in controls).
In contrast to the anti-TNF therapy, the status of disease activity did not influence the level of reduction. MMP levels were reduced in a similar manner in the JIA children regardless of disease activity status and the reduced MMP levels were not statistically different; in fact, they were almost identical in active JIA and non-active JIA children (Figure 1-3) .
General Sialochemistry
The salivary calcium concentrations were altered in a similar manner as those of the MMPs in the control and JIA children. Phosphate concentrations demonstrated opposite trends though these did not reach statistical significance.
Thus a significant decrease in calcium concentration was found in JIA patients compared with healthy control children. The median value of calcium in the control group was 2.35 mg/dL, whereas in the JIA children this value was lower by 23.5% (P = 0.045).
The median salivary phosphate concentrations of the control and JIA children were not significantly different (NS): 13.3 mg/dL and 10.9 mg/dL, respectively.
The phosphate concentrations of the anti-TNF treated and untreated children were similar, 13.6mg/dL and 12.9 mg/dL, respectively. In the JIA active versus JIA non-active children these values were 13.1 mg/dL (NS) and 14.0 mg/dL (NS), respectively. The salivary total protein concentrations in the controls and JIA patients were 50.5 mg/dL (NS) and 49.3 mg/dL (NS), respectively. Neither were any significant alterations found n the total protein concentrations of the JIA subgroups: active versus non-active or anti-TNF treated versus untreated subgroups.
Oxidative Analysis
In contrast to the MMPs, most of the analyzed antioxidative parameters demonstrated the opposite trend, that is, a substantial increase in salivary antioxidants in the JIA children ( Table 1) . The median salivary antioxidant values of the TAS, ImAnOx, UA, SOD and SPO in the controls were 0.27 mmol/L, 193 umol/L, 0.70 mg/dL, 1.2 U/mL and 0.51, respectively, while that of the carbonyls (the only oxidative parameter analyzed) was 0.087 nmol/mg. The TAS, ImAnOx, UA and carbonyls increased substantially in the JIA children, more so when the disease was active, while the SOD and the SPO values remained virtually unchanged. The change in the TAS, ImAnOx and SPO median levels reached statistical significance and more so when the disease was active. Hence, in the JIA children (all patients group) the TAS was higher by 44% (P = 0.01), the ImAnOx by 24.8% (P = 0.04), the SPO by 6.1% (P = 0.009), the carbonyls by 85% (NS), the UA by 14.2% (NS) and the SOD by 8.7% (NS). In the JIA-active subgroup the median levels of UA, TAS and carbonyls were higher by 142% (P = 0.01), 68% (NS) and 25% (NS), respectively, as compared with the JIA non-active children ( Table 1) . The further increase in the antioxidant potential of the JIA-active group was also accompanied by total prevention of an increase in carbonyls, and hence the carbonyl concentration of the controls and the JIA-active children was identical.
The anti-TNF treatment made no difference with respect to the JIA-induced increase in antioxidants, and there were no statistical differences in the antioxidant parameters among the anti-TNF treated versus untreated subgroups (Table 1) .
Spearman Correlation Analysis
The Spearman analysis revealed high correlation rates for MMP-3 and MMP-2; MMP-3 and MMP-9; and MMP-2 and MMP-9 which were r = 0.89 (P = 0.0001); r = 0.80 (P = 0.0001) and r = 0.79 (P = 0.0001), respectively. The analysis revealed moderate correlation rates for MMP-3 and Ca; MMP-9 and Ca and MMP-2 and Ca which were r = 0.46 (P = 0.001); r = 0.40 (P = 0.007) and r = 0.41 (P = 0.004), respectively.
Sensitivity, Specificity
The sensitivity values for salivary MMP-2, MMP-3, MMP-9 and TAS concentrations (based on cutoff value = mean ± 1 STD), were 80%, 74%, 66% and 51%, respectively, while for the speci- ficity values they were 81%, 81%, 88% and 75%, respectively.
DISCUSSION
The currently reported data demonstrate a significant enhancement of the salivary antioxidant system in JIA patients which is even greater when the disease is in its active state. This was demonstrated by various analyzed parameters, including the uric acid molecule (which is considered responsible for no less than 70% of the salivary antioxidant potential (25) (26) (27) and the two general salivary antioxidant analyses performed-TAS and ImAnOx. Concurrently we report, for the first time, that salivary MMPs are reduced in JIA and more so following anti-TNF therapy. This is accompanied by a similar reduction in salivary calcium. These results are important at the diagnostic level and also for their value concerning the pathogenesis of the disease, considering the highly significant reductions concomitantly demonstrated for all three MMPs examined and the high correlation rates among these reductions. Simple kits for salivary MMP detection may be used by children or their parents for diagnostic purposes. The relatively high sensitivity and specificity scores obtained may be further improved if various MMPs were examined simultaneously. However, the results of JIA-related reductions of MMPs 2, 3 and 9 in the saliva are puzzling, as these specific MMPs were found to be increased in the serum and in the synovial fluid of JIA and rheumatoid arthritis (RA) patients (14) (15) (16) (17) . It is well established that most enzymes found in the saliva originate from the salivary or oral mucosal cells and not from the serum (28) . This could explain an absence of increase in the salivary MMP in JIA, but not a decrease. Therefore, we should look for a mechanism which is related to JIA and its local effects on saliva.
In contrast to what is expected due to data reporting the increase of MMP-2, MMP-3 and MMP-9 in the serum, the fact that all three MMPs were reduced in the saliva seems to indicate the presence of a local mechanism. The currently reported increase in various salivary antioxidant parameters is of no surprise; in recent years, oxidative stress has become increasingly recognized as one of the major factors contributing to the chronic inflammatory process both in RA and in JIA patients (9, 11, (29) (30) (31) (32) (33) . Furthermore, increased MMP expression and activity was reportedly induced by the greater oxidative stress in general and also in rheumatoid synovial cells, as was shown in numerous studies; and vice versa, MMP expression and activity was decreased by antioxidants such as vitamin E or SOD (18, (34) (35) (36) (37) (38) (39) (40) . It is also worth noting recent reports demonstrating that the bioflavonoid Hesperidin protects against the effects of nicotine by reversing the nicotine-induced parallel increase of both oxidative stress and enhanced MMP expression (19, 41, 42) . In another study, bioflavonoids, which are antioxidants and antiinflammatory drugs, inhibited the elevation of intracellular calcium and the production of the proinflammatory cytokines TNF-α and IL-6 in a model of mast cell-mediated inflammation (43) . Oxidative stress also was shown to induce various inflammatory mediators of rheumatoid arthritis, such as prostaglandins formed by Cox-2 in the synovium (44) . Such proinflammatory cytokines have been shown to induce MMPs and, therefore, it is not surprising that anti-TNF therapies have been found to reduce serum MMP levels in patients with RA (11) (12) (13) (14) . Indeed, Mentzel et al., (45) who studied a rat model for antigen-induced arthritis, reported that TNF-α increased total MMP activity, levels of IL-6 and oxidant nitric oxide (NO) in the supernatants of synoviocytes, and induced the expression of MMP9 (as did IL-1β). There is a demonstrated association between calcium release from various cells following their exposure to oxidative stress which is reported to be accompanied by increased MMP activity (34) (35) (36) (37) 46) . There also are reports demonstrating that calcium-phosphate crystals normally associated with rheumatic syndromes stimulate a variety of inflammatory mediators such as prostaglandin E (2), NO, IL-1β and MMPs (47, 48) .
In summary, we suggest that the increase in salivary antioxidant capacity in JIA leads to a local abrogation of its pathological network, resulting in substantial hindrance of produced carbonyls as well as a significant reduction in salivary MMPs and calcium. This was enhanced further by the anti-TNF therapy, which intervened with another pivotal component of this network, the major proinflammatory mediator. The significance of these results at the diagnostic level has been discussed earlier. However, we think that this may have possible implications on future therapy as well, and we suggest adding antioxidant therapy to the JIA patients, both locally and systemically.
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